Patents by Inventor Anne-Isabelle Michou

Anne-Isabelle Michou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6841158
    Abstract: Recombinant CELO virus or CELO virus DNA with a deletion at the right end of the viral genome that allows insertion of large pieces of foreign DNA. The virus is useful as a vaccine for animals, in particular birds, and for gene therapy and vaccine applications in humans. The virus can also be used for recombinant protein production.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: January 11, 2005
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthew Cotten, Anne-Isabelle Michou, Gerhard Christofori, Amelia Compagni
  • Patent number: 6797506
    Abstract: Recombinant CELO virus or CELO virus DNA with a deletion or disruption of the Gam1 gene, optionally combined with deletions at the right or left end of the viral genome that allow insertion of large pieces of foreign DNA. The virus is useful as a vaccine for animals, in particular birds, and for gene therapy and vaccine applications in humans. The virus can also be used for recombinant protein production.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: September 28, 2004
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthew Cotten, Jolanta Glotzer, Anne-Isabelle Michou
  • Patent number: 6399587
    Abstract: The invention concerns a recombinant adenoviral vector driving from an adenovirus genome at least by deleting all or part of the E1 region, the adenoviral vector comprising an expression cassette of a gene of interest placed under the control of elements necessary for its expression in a host cell or a host organism, the elements required for its expression including at least a splicing sequence. The invention is characterized in that the splicing sequence is derived from a eukaryotic nuclear gene selected among the ovalbumen genes, &bgr; or &bgr;-globine, collagen and factor VIII of mammals or a synthetic splicing sequence. The invention also concerns a host cell and an infectious viral particle comprising such a vector, a method for preparing such a particle and their therapeutic or prophylactic use. The invention further concerns a pharmaceutical composition containing the adenoviral vector, the host cell or the viral particle.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: June 4, 2002
    Assignee: Transgene S.A.
    Inventors: Majid Mehtali, Pierre Leroy, Anne-Isabelle Michou